SCHEDULE: Patient Capital Boosts Stake in Precigen to 10.18%

Patient Capital Management and Patient Opportunity Trust have increased their beneficial ownership in Precigen, Inc. to 10.18% and 7.8% respectively.

Summary

• Patient Capital Management, LLC is the beneficial owner of 36,006,800 shares of Precigen, Inc. common stock.
• This represents 10.18% of the class of securities.
• Patient Opportunity Trust, a Series of Advisor Managed Portfolios, is deemed the beneficial owner of 27,617,612 shares of common stock.
• This represents 7.8% of the class of securities.
• Patient Capital Management, LLC holds sole voting and sole dispositive power over its 36,006,800 shares.
• Patient Opportunity Trust holds sole voting and sole dispositive power over its 27,617,612 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. The increased and significant institutional ownership by Patient Capital Management and Patient Opportunity Trust suggests a vote of confidence in Precigen, Inc., without indicating any intent to influence control.

Positives

• Increased institutional ownership by Patient Capital Management, LLC and Patient Opportunity Trust may signal confidence in Precigen's long-term prospects.
• The filing explicitly states that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control, which suggests a passive investment strategy.

Negatives

• No direct negatives are presented in this ownership disclosure filing.

Risks

• No specific risks related to the company's operations or financial health are disclosed in this Schedule 13G filing, as it pertains solely to beneficial ownership.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Precigen's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that significant institutional ownership, such as the 10.18% stake held by Patient Capital Management, is common in the biotechnology sector. Such investments often reflect a long-term view on the potential of a company's pipeline or technology, especially given the extended development cycles and regulatory hurdles inherent in the industry. This level of ownership by an investment adviser and investment company can provide a degree of stability to the shareholder base.

Comparison to Industry Standards

• Institutional ownership levels for biotech companies can vary widely, but a 10.18% stake by a single investment manager is a notable position, indicating a strong conviction in Precigen's value proposition.
• Compared to industry benchmarks, a significant institutional stake can be viewed positively, as it often implies thorough due diligence and a belief in the company's long-term growth potential, similar to large institutional holdings seen in companies like Moderna (MRNA) or BioNTech (BNTX) by major asset managers.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may be viewed positively, potentially increasing investor confidence and liquidity.
• Company Management: Awareness of a large, passive institutional investor may influence strategic decisions, though the filing explicitly states no intent to influence control.

Key Dates

Recommendation

The filing indicates a significant institutional investor has increased its stake, which can be a positive signal. However, a Schedule 13G filing primarily reports ownership and does not provide operational or financial performance details. Without further information on Precigen's fundamentals, pipeline progress, or market conditions, a 'hold' recommendation is prudent for a seasoned investor. The increased institutional confidence supports maintaining existing positions, but a 'buy' would require more comprehensive data.

Keywords

Precigen, Patient Capital Management, Patient Opportunity Trust, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Schedule 13G, Biotechnology, Healthcare